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Cognitive disabilityCortical gray matter (GM) damage is now widely recognized in multiple sclerosis (MS). The standard MRI does
not reliably detect cortical GM lesions, although cortical volume loss can be measured. In this study, we demon-
strate that the gradient echo MRI can reliably and quantitatively assess cortical GM damage inMS patients using
standard clinical scanners. High resolution multi-gradient echo MRI was used for regional mapping of tissue-
speciﬁc MRI signal transverse relaxation rate values (R2*) in 10 each relapsing–remitting, primary-progressive
and secondary-progressive MS subjects. A voxel spread function method was used to correct artifacts induced
by background ﬁeld gradients. R2* values from healthy controls (HCs) of varying ages were obtained to establish
baseline data and calculateΔR2* values – age-adjusted differences betweenMSpatients andHC. Thickness of cor-
tical regions was also measured in all subjects. In cortical regions, ΔR2* values of MS patients were also adjusted
for changes in cortical thickness. Symbol digit modalities (SDMT) and paced auditory serial addition (PASAT)
neurocognitive tests, as well as Expanded Disability Status Score, 25-foot timed walk and nine-hole peg test re-
sults were also obtained on all MS subjects. We found that ΔR2* values were lower in multiple cortical GM and
normal appearing white matter (NAWM) regions in MS compared with HC. ΔR2* values of global cortical GM
and several speciﬁc cortical regions showed signiﬁcant (p b 0.05) correlations with SDMT and PASAT scores,
and showed better correlations than volumetric measures of the same regions. Neurological tests not focused
on cognition (Expanded Disability Status Score, 25-foot timedwalk and nine-hole peg tests) showed no correla-
tion with cortical GM ΔR2* values. The technique presented here is robust and reproducible. It requires less than
10min and can be implemented on anyMRI scanner. Our results show that quantitative tissue-speciﬁc R2* values
can serve as biomarkers of tissue injury due toMS in the brain, including the cerebral cortex, an area that has been
difﬁcult to evaluate using standard MRI.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple sclerosis (MS) is an inﬂammatory demyelinating disease of
the brain, optic nerves and spinal cord. Involvement of gray matter ing–remitting multiple sclerosis;
mary-progressivemultiple scle-
ormal appearing white matter;
SDMT, symbol digit modalities
, 25-foot timed walk; 9HPT,
aging;MPRAGE,magnetization
MLL, white matter lesion load;
y, Washington University, 660
USA. Tel.: +1 314 362 3293;
. This is an open access article underMS has long been recognized in pathology studies (Bö et al., 2007;
Dawson, 1916; Klaver et al., 2013; Pirko et al., 2007; Schutzer et al.,
2013), yet MS has been considered to be predominantly a white matter
disease due to more readily detected focal inﬂammatory demyelinating
pathology inwhitematter by histology and byMRI. Evidence exists that
damage occurs frequently inNAWM(Allen et al., 2001;Moll et al., 2011;
Zeis et al., 2008) and cortical gray matter (Geurts et al., 2005a; Kidd
et al., 1999; Kutzelnigg et al., 2005). Damage occurring in each of
these regions contributes to brain atrophy seen commonly in MS
(Bermel et al., 2003; Sharma et al., 2004). Importantly, cortical lesions
and cortical atrophy (which are presumed to be linked) are early ﬁnd-
ings in many RRMS patients, and correlate with disability, especially
cognitive disability (Calabrese et al., 2009a; Charil et al., 2007;
Zivadinov et al., 2013). Loss of cortical volume in MS does not occur in
a uniform pattern, but is seen more often in speciﬁc regions such as
the cingulate gyrus and insular regions (Charil et al., 2007).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nique has been challenging. Although conventional T2-weighted
and FLAIR MRI sequences can detect many white matter lesions,
these sequences do not readily detect damage in cortical gray mat-
ter or NAWM. Many MRI techniques, such as DIR (double inversion
recovery) (Calabrese et al., 2007b; Geurts et al., 2005b; Geurts et al.,
2011), diffusion (Hulst et al., 2013; Llufriu et al., 2014; Vrenken
et al., 2006), MT (magnetization transfer) (Chen et al., 2013;
Derakhshan et al., 2014a, 2014b; Schmierer et al., 2010; Seewann
et al., 2011; Yarnykh et al., 2015) and transverse relaxation rate re-
lated measurement at ultra-high ﬁeld (Absinta et al., 2015; Mainero
et al., 2015), have been used to improve the detection of cortical MS
damage. However, for various reasons, none of them have made it
into clinical practice yet.
Gradient echo plural contrast imaging (GEPCI) is a technique based
on a gradient recalled echo sequence with multiple gradient echoes
(Luo et al., 2012; Sati et al., 2010; Yablonskiy, 2000). GEPCI allows si-
multaneous generation of naturally co-registeredmulti-contrast images
(T1-weighted or spin density images, quantitative tissue-speciﬁc T2* or
R2* maps and frequency maps) from a single MRI scan. By combining
basic GEPCI images, additional images can be generated, such as SWI-
like images, GEPCI-SWI images, T1f images, Fluid suppressed T2*
(FST2*) images, and SWI-T2* images (Luo et al., 2012). Previously,
using the quantitative nature of GEPCI R2* measurements, we intro-
duced quantitative GEPCI scores of tissue damage in WM lesions (Sati
et al., 2010) and demonstrated in a small cohort that quantitative
GEPCI scores of cerebral WM (not including GM) correctly categorized
patients into RRMS vs. SPMS vs. PPMS in 70% of cases (Luo et al.,
2014). GEPCI phase images also demonstrated a potential for early MS
lesion detection (Yablonskiy et al., 2012).
In this study, we use two outcomes of GEPCI approach – quantitative
tissue speciﬁc R2*maps andGEPCI T1weighted images – to study 29MS
subjects and 21 healthy controls. We applied R2* analysis to evaluate
global and regional tissue integrity in MS brains, with particular focus
on the cortical gray matter. The results showed signiﬁcant differences
between the healthy andMS cohorts. R2* results correlatedwith clinical
and neurocognitive test scores in the MS group. Based on quantitative
R2* analysis, we introduced an exhibition method, “GEPCI-barcode,” to
illustrate the severity of tissue damage in different brain regions inTable 1
Summary of subject demographic and clinical information.
MS
RRMS
Number 10
Mean age ± SD
(range)
49.4 ± 10.4
(32–60)
Female/male 9/1
SDMT mean ± SD (range) 54.6 ± 10.9
(32–68)
3 s PASAT mean ± SD (range) 49.0 ± 11.6
(21–59)
EDSS mean ± SD
(range)
3.05 ± 1.7
(1–6.5)
25FTW mean ± SD
(range)
5.9 ± 2.5
(3.86–12.5)
9HPT mean ± SD (range) Dominant 23.4 ± 4.8
(16.62–30.19)
Non-dominant 28.2 ± 12.8
(17.55–61.95)
WMLL (ml) mean ± SD
(range)
12.1 ± 13.0
(1.3–40.1)
NCGMV (ml) mean ± SD
(range)
757.2 ± 47.5
(703.2–835.0)
SDMT= symbol digit modalities test; PASAT = paced auditory serial addition test; EDSS = ex
WMLL = white matter lesion load; NCGMV= normalized cortical gray matter volume.individual subjects, and to allow easy evaluation of local tissue damage
based on R2* measurements.
2. Materials and methods
2.1. Subjects
Thirty MS patients with prior and clear designations as having
relapsing remitting, secondary progressive or primary progressive
clinical courses were invited to enroll in the study. MRI scans were
collected from 10 RRMS, 10 PPMS and 10 SPMS patients. Data from
one SPMS subject could not be included in ﬁnal analyses because
of pervasive “cloud-like” artifacts (Wen et al., 2014) caused by phys-
iological ﬂuctuations during the scan. The twenty one normal
healthy control volunteers consisted of seven males and fourteen fe-
males, ranging in age from 21 to 74 years (age mean ± SD: 44.3 ±
14.9), were speciﬁcally chosen to represent the age range of the
MS patients (Table 1). All studies were approved by the Institutional
Review Board of Washington University in St Louis. All subjects pro-
vided informed consent.
2.2. Clinical testing
EDSS, a standardized neurological examination validated for use in
MS, was performed by a certiﬁed examiner (AHC). Additionally, gait
was assessed by 25FTW and bilateral upper extremity function was
assessed by 9HPT. The PASAT, a test of auditory information processing
speed and calculation ability, and SDMT, a test of visual processing
speed, each validated in MS, were used to assess cognition. All testing
was performed by experienced examiners on the same day as MRI,
without knowledge of the imaging results.
2.3. Image acquisition
All MRI scans were collected using a 3.0 Tesla (3 T) TrioMRI scanner
(Siemens, Erlangen, Germany) equipped with a 12-channel phased-
array head coil. High resolution GEPCI (Luo et al., 2012; Sati et al.,
2010; Yablonskiy, 2000) datasets with a voxel size of 1 × 1 × 3 mm3
were acquired using a three dimensional (3D) multi-gradient-echoNormative data
PPMS SPMS
10 9
55.2 ± 10.2
(37–74)
59.2 ± 9.3
(45–75)
6/4 7/2
42.5 ± 14.5
(10–61)
44 ± 15.2
(18–63)
62.1 ± 10.7 (Strober et al., 2009)
40.4 ± 11
(21–56)
37.9 ± 16
(15–58)
49.7 ± 9.8 (Strober et al., 2009)
5.1 ± 1.3
(3.5–6.5)
5.5 ± 1.1
(4–6.5)
n/a
10.2 ± 9
(4.17–34.315)
13.4 ± 11
(5.5–41.08)
≤5 (Kaufman et al., 2000)
30.1 ± 9.8
(22.7–56.2)
27.5 ± 5.3
(19.9–34.69)
≤22 (Oxford Grice et al., 2003)
31.3 ± 5.8
(24.05–41.45)
38.4 ± 19.1
(21.7–75.85)
13.1 ± 9.6
(2.3–29.2)
13.9 ± 10.0
(6.4–36.7)
730.9 ± 55.8
(648.9–844.4)
678.3 ± 61.1
(551.2–759.1)
panded disability status scale; 25FTW= 25-foot timed walk; 9HPT = nine-hole peg test;
Fig. 1. Flowchart of ROI creation. A. Calculation of T1-weighted images and R2* maps from
raw data, brain was extracted using BET tool in FSL; B. Freesurfer used for brain segmen-
tation; C. generation of regional masks based on the segmentation; D. registration of
MPRAGE image onto GEPCI-T1-weighted image; E. regional masks mapped onto GEPCI
images; F. GEPCI-T1w images used to generate CSF mask; G & H. calculation of median
values of the R2* distribution in each ROI.
166 J. Wen et al. / NeuroImage: Clinical 9 (2015) 164–175sequence with a ﬂip angle of 30°, TR= 50ms and total acquisition time
of 6 min 30 s. For each acquisition, 11 echoes were collected with ﬁrst
echo time TE1 = 4 ms and echo spacing ΔTE = 4 ms. The multi-echo
datasets were used for calculation of R2*. Standard clinical MPRAGE
(Mugler and Brookeman, 1990) images with high resolution (voxel
size: 0.94 × 0.94 × 1.5 mm3) were also collected for segmentation
purposes.
2.4. Image processing
Raw k-space data were read intoMATLAB (TheMathWorks, Inc.) for
processing. After applying Fourier transform to the k-space, data from
different channels were combined for each voxel in a single data set
S(TE) using a strategy developed in house (Luo et al., 2012; Quirk
et al., 2009):
SðTEÞ ¼ 1
M
XM
m¼1
λmSðTE1ÞSmðTEnÞ
λm ¼ 1M
XM
l¼1
σ2l =σ
2
m
ð1Þ
where the sum is taken over all channels (m), Sdenotes complex conju-
gate of S, λm is the weighting parameter and σm is the noise amplitude
(r.m.s.). We omit index corresponding to voxel position for clarity.
This algorithm allows for the optimal estimation of quantitative param-
eters, such as magnetic resonance signal decay rate constants and also
removes the initial phase incoherence between channels. R2* constants
were obtained by ﬁtting the channel-combined data on a voxel-by-
voxel basis using the following theoretical model:
SðTEÞ ¼ S20  e−R

2 ðTEþTE1Þ  eiω ðTE−TE1Þ  FðTEÞ ð2Þ
whereω is a local signal frequency and F(TE) is the F-function describing
the inﬂuence of macroscopic magnetic ﬁeld inhomogeneity effects on
MRI signal (Yablonskiy, 1998). Herein, we use a voxel spread function
algorithm (Yablonskiy et al., 2013) for evaluation of F-function. With
our choice of TR and ﬂip angle, S0 represents T1-weighted images.
Brain segmentation and volumetric information was obtained from
MPRAGE images using FreeSurfer (Martinos Center for Biomedical Im-
aging, MGH/HST, US). Then, ROIs were registered on GEPCI-T1w images
using FSL (Analysis Group, FMRIB, Oxford, UK). Last, regional R2* medi-
an values were generated and used for further analysis, as shown in
Fig. 1. Note that to minimize the partial volume effect, CSF masks were
also generated based on the GEPCI T1w images using FSL (step F in
Fig. 1). Volumetric data were calculated from the segmentation results
by multiplying the number of voxels inside each brain region by the
size of voxels. Then, normalization factors were calculated using the
“SIENAX” tool in “FSL” and applied to each region to get normalized vol-
umes. Normalized brain volume (NBV) data were also obtained from
the “SIENAX” results in “FSL”.
2.5. ROI creation
First (step A in Fig. 1), GEPCI-T1-weighted (S0) images and R2* maps
were generated according to Eq. (2). Both GEPCI-T1-weighted and
GEPCI-R2* images were put into FSL (Jenkinson et al., 2012; Smith
et al., 2004; Woolrich et al., 2009) to remove the skull. Then, MPRAGE
images were put into FreeSurfer (Laboratory for Computational Neuro-
imaging, Martinos Center for Biomedical Imaging) to generate brain
segmentations and regional masks (steps B and C in Fig. 1), which in-
clude masks for global and regional cortical gray matter, NAWM and
deep gray matter (caudate, putamen, globus pallidus and thalamus).At the same time, after removing skull using FSL, MPRAGE images
were registered to GEPCI-T1-weighted images using FMRIB3s Linear
Image Registration Tool (Jenkinson et al., 2002; Jenkinson and
Smith, 2001) in FSL (step D in Fig. 1) to get registration matrices.
Then, the registration matrices were used to map the segmentation
on GEPCI-R2* maps (step E in Fig. 1), which are naturally co-
registered with GEPCI-T1-weighted images when using the GEPCI
technique. To minimize the partial volume effect, CSF masks were
also generated based on the GEPCI T1 weighted images using FSL
(step F in Fig. 1). Note that in step B for MS subjects, we ﬁrst used
MPRAGE and FLAIR images to get WM lesion mask using the
“lesion-TOADS” tool (Shiee et al., 2010) in MIPAV (McAuliffe et al.,
2001). Then, we ﬁlled the lesion areas with averaged signal from
normal tissue. These lesion-ﬁlled-MPRAGE images were used for
segmentation for MS subjects. By doing this, we can minimize the
topological defects caused by large lesions.
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All statistical analyses were performed using MATLAB (The
MathWorks, Inc.). For each ROI generated as described above,
there was a distribution of R2* for which a median value was calcu-
lated. Median R2* values were used because distribution functions in
each region were not symmetric. Regional R2* median values were
calculated for each FreeSurfer region in each subject by applying re-
gional and CSF masks to GEPCI R2* maps. Because age affects R2*
(Siemonsen et al., 2008) and volume (Ge et al., 2002), MS subject
data were corrected for age using baseline data obtained from the
healthy subject cohort. Linear regression analysis of median R2*
values was used to deﬁne age-dependent baseline median R2*
values for each region. Based upon this formula, for each ROI for
each MS subject, the age-dependent baseline median R2* value for
the healthy control subjects was subtracted from the MS subject3s
R2* median value to obtain the age-corrected parameter, ΔR2*. The
same procedure was used to create age-corrected tissue volumes,
termed ΔV. In cortical GM regions, due to partial volume effect,
variation in cortical thickness was also taken into account. In these
regions, we adjusted R2* with respect to both age and cortical thick-
ness using multiple linear regression to create ΔR2*. For each brain
ROI, ANOVA was used to compare ΔR2* and ΔV of the HC with MS
subjects representing three clinical subtypes. Pearson3s correlation
was used to evaluate the correlation between ΔR2* or ΔV values
and clinical scores. Correlation coefﬁcients (r) and p-values
(p) were calculated. False discovery rate was used to correct for
multiple comparisons. In all cases, a p-value b0.05 was considered
as statistically signiﬁcant.
2.7. GEPCI-barcode
To allow easier assimilation and comparison of the separate cortical
regions, NAWM and deep gray matter regions being examined in eachFig. 2.ΔR2* and normalized volumes (ΔV) of global cortical GMandNAWM for HC andMS coho
for ΔV values in global brain cortical GM; C. group comparisons for ΔR2* values in NAWM; D. gindividual, we developed a visualization method we named “GEPCI
barcode” to not only show easily distinguishable differences between
healthy and MS cohorts and among different subtypes, but also to pro-
vide a potentially machine-readable representation of data relating to
the regional abnormalities for each individual. For each brain ROI, the
mean values (MEANHC) and standard deviations (STDHC) of the ΔR2*
values of the healthy group were calculated. Then, z-scores were calcu-
lated for all ROIs of each MS subject using:
z ¼ ΔR2

MS−MEANHC
STDHC
ð3Þ
where is the ΔR2* value calculated from distinct brain ROIs of each MS
subject. All brain ROIs with z-scores between−1.96 and 1.96were con-
sidered as normal and are shown aswhite squares on the barcode. Brain
ROIs with z-scores less than−1.96 but greater than−2.58were consid-
ered as regions with damage and are shown as unﬁlled red squares.
Brain ROIs with z-scores less than −2.58 were considered as regions
with severe damage, and were assigned completely red squares. Brain
regions with z-score greater than 1.96 were considered as regions
with high R2* values of unclear signiﬁcance, and were designated un-
ﬁlled blue (z-score greater than 1.96 but less than 2.58) or fully blue
squares (z-score N 2.58) on the barcode.
3. Results
3.1. Cortical ROIs
ΔR2* values of the HC andMS cohorts in the global and regional cor-
tical GM ROIs were compared. Data from right and left sides for individ-
ual regionswere combined. TheMS cohort showed lowerΔR2* values in
the global cortical GM, compared with the HC cohort (Fig. 2A). Whenrts. A. Group comparisons forΔR2* values in global brain cortical GM; B. group comparisons
roup comparisons for ΔV values in NAWM.
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ΔR2* values and had the greatest number of abnormal regions, with sig-
niﬁcantly (p b 0.05) lower ΔR2* values in 25 of 31 cortical regions com-
pared with the same regions in the HC (Table A.1). MS subjects also
showed signiﬁcantly reduced ΔV values. Although many regions with
reduced ΔV values also had reduced ΔR2* values, in a few regions ΔV
was more sensitive whereas in others ΔR2* was more sensitive to ab-
normalities. Progressive MS subjects had more severe age-adjusted
brain atrophy, compared to RRMS subjects. PPMS cohort had signiﬁ-
cantly decreased ΔV in 18 of 31 cortical regions, while SPMS cohort
had signiﬁcantly decreased ΔV in 24 of 31 cortical regions, compared
to HC (Fig. 2B & Table A.1).3.2. Non-neocortical brain ROIs
Fig. 2C reveals that theMS cohorts had lower ΔR2* values in NAWM
compared with the HCs. Signiﬁcant NAWM volume loss was also found
in RRMS and SPMS subjects (Fig. 2D). In the globus pallidus (Table A.1),
theΔR2* values in the RRMS cohort were higher than theΔR2* values in
HC. SPMS and PPMS cohorts had overall higher ΔR2* in globus pallidus
than the HC cohort but lowerΔR2* than the RRMS cohort. No signiﬁcant
differences were found for ΔR2* values in the caudate, putamen and
thalamus regions between HC and any of the MS cohorts (Table A.1).
ΔV values were signiﬁcantly reduced in the putamen, globus pallidus,
caudate and thalamus inMS subjects (Table A.1). Signiﬁcant correlation
was found between ΔR2* changes in the cortex and in the thalamus
(r = 0.43, p = 0.002). Only moderately signiﬁcant correlation was
found between ΔR2* changes in the cortex and in the caudate
(r = 0.31, p = 0.03) regions. No signiﬁcant correlations wereFig. 3. Cognitive test correlations with ΔR2* and with normalized whole brain volumes (ΔNBV
global cortical GM with 3 s PASAT; C. correlation between ΔNBV and SDMT; D. correlation bet
ﬁgure. Each point represents an individual subject.ΔNBV is the normalizedwhole brain volume
cortical GM volumes and cognitive test scores (Table A.2).found between ΔR2* changes in the cortex and in putamen or globus
pallidus regions.3.3. Correlations between regional ΔR2* and ΔV values and clinical tests
SDMT and PASAT assess visual workingmemory speed and auditory
working memory speed, respectively. ΔR2* values calculated from the
global cortical GM region correlated signiﬁcantly with SDMT (r =
0.60, p b 0.001) and 3 s PASAT (r = 0.53, p = 0.003) cognitive tests
(Fig. 3A & B).
ΔR2* values in the hippocampus and many individual cortical re-
gions also showed signiﬁcant correlationswith SDMT and PASAT scores
aswell (Table A.2).ΔR2* values of several cortical regions correlated sig-
niﬁcantly (r N 0.4, p b 0.05) with cognitive tests (ROIs in “bold” in
Table A.2). Correlations between cognitive tests and age-adjusted
whole brain volumes (ΔNBV) were also found (Fig. 3C & D), but no sig-
niﬁcant correlations were found between normalized regional age-
adjusted volumes of cortical GM and cognitive test scores (Table A.2).
Themultiple linear regressionmethodwas also used to test correlations
between cognitive scores (SDMT and PASAT) and MRI measurements
(ΔR2* of cortical graymatter;ΔNCGMV: age-adjusted normalized corti-
cal GM volume;WMLL: white matter lesion load). For SDMT scores, the
p-values for ΔR2*, ΔNCGMV and WMLL were 0.003, 0.65 and 0.05, re-
spectively. For PASAT scores, the p-values for ΔR2*, ΔNCGMV and
WMLL were 0.005, 0.35 and 0.75, respectively. The EDSS, 25FTW and
9HPT, neurological tests that primarily assess strength, coordination,
gait, and upper extremity function, showed no signiﬁcant correla-
tions with global or regional cortical GM ΔR2* values. The 25FTW
correlated inversely with ΔNBV (r = −0.37, p = 0.047) and). A. Correlation of ΔR2* of global cortical GM with SDMT scores; B. correlation of ΔR2* of
ween ΔNBV and 3 s PASAT. Correlation coefﬁcient (r) and p-values (p) are listed in each
after age correction. No signiﬁcant correlationswere found between regional age-adjusted
Fig. 4. Cortical z-score brain maps of ΔR2* in healthy, RRMS, PPMS and SPMS groups. For each cortical regions in each group, averaged z-scores were calculated across all subjects.
169J. Wen et al. / NeuroImage: Clinical 9 (2015) 164–175normalized age-adjusted GM volume (r = −0.41, p = 0.026). No
other correlations were found for ΔV values.
3.4. GEPCI-barcode
Averaged cortical z-score maps (from which GEPCI barcodes are
derived) for four groups are shown in Fig. 4. From these z-score maps,
it is apparent that most SPMS subjects have much lower GEPCI
z-scores affecting almost the entire cortex.
Fig. 5 shows a summary barcode for all the subjects. As expected,
most brain regions in the HC subjects were normal (white, Fig. 5).
Four HC subjects showed abnormally low ΔR2* values in a few regions
(1.2% of all regions, 1.2% of cortical GM regions in all HCs). This may
be explained becausewe selected [−1.96, 1.96] as a range to deﬁne nor-
malΔR2*, which contained about 95% of the total regions in HC subjects
with the other 5% located outside the normal range. It is also possible
that those HC subjects had real abnormalities of unknown etiology. In
contrast, many brain regions of theMS subjects were abnormal (red un-
ﬁlled or red ﬁlled squares for lowΔR2*; or blue unﬁlled or ﬁlled for high
ΔR2*, Fig. 5). For cortical graymatter, the percentage of regionswith ab-
normal tissue integrity based on GEPCIΔR2* values for RRMS, PPMS and
SPMS subjects was 0%, 30% and 67%, respectively.
Cortical damage, inferred from the reduced ΔR2* values, was more
widespread in the SPMS cohort than the other two MS clinical subtype
cohorts as illustrated with “GEPCI-barcode”, with 8 of 9 SPMS subjects
displaying several cortical regions of reduced ΔR2*. Interestingly, 3 of
those 7 did not display reduced ΔR2* in NAWM, supporting the ﬁnding
that damage to cortical gray matter and white matter is not highly
linked (Sbardella et al., 2013).
Using the GEPCI-barcode, 10% of RRMS, 30% of PPMS and 33% of
SPMS subjects showed abnormally low ΔR2* (red & black) in NAWM
(Fig. 5). Regarding deep gray matter regions, in the globus pallidus,
50% of RRMS showed abnormally high ΔR2*, with fewer of the PPMS
(10%) and SPMS (22%) groupswith increasedΔR2* in deep graymatter.
4. Discussion
In this study, we used tissue speciﬁc quantitative R2* values as bio-
markers for tissue alterations in MS brain with particular attention to
the global and regional cerebral cortex where tissue damage is poorly
appreciated using standard MRI techniques. Our results conclusively
support the known neuropathology of MS as a global brain disease af-
fecting both gray and white matter. The GEPCI technique, which re-
quires less than 7 min to acquire on standard clinical MRI scanners,
detected abnormalities within regions without visible lesions, such as
cortical gray matter, NAWM and deep gray matter. The measured R2*
values were referenced to age-dependent HC values. The majority of
white matter abnormalities were reductions in R2*, which were indica-
tive of damage based on our and others3 earlierwork (Cohen-Adad et al.,2011; Pitt et al., 2010; Sati et al., 2010). Further, we developed a presen-
tation technique called “GEPCI-barcode” to display these quantitative
results intuitively.
MS is a demyelinating disease of the CNS, the cause of which is yet
unknown. Because it is demyelinating, it has long been considered as
a white matter disease, despite the fact that myelin is also present in
gray matter and initial pathology studies in the early and mid-1900s
had demonstrated that both white matter and graymatter are involved
(Brownell and Hughes, 1962). Reasons for the lack of attention to gray
matter pathology include that focal inﬂammatory demyelination in
gray matter provides less contrast using standard histological stains
(e.g. Luxol fast blue andhematoxylin) because of the lower baselinemy-
elin content and less prominent cellular inﬂammation in graymatter le-
sions comparedwithwhitematterMS lesions.Moreover, the pathologic
changes in white matter create more conspicuous manifestations on
MRI, including not only the typical hyperintensities on T2w images,
but in some cases hypointensities (“black holes”) on T1w images. The
latter are practically never seen in gray matter. In addition to being dif-
ﬁcult to detect on T1w and T2w images, cortical gray matter lesions
have only rarely been described to enhance post-gadolinium (Popescu
et al., 2011).
Yet, cortical gray matter lesions are exceedingly important in MS,
and can occur very early in disease (Chard et al., 2004). Conservatively,
cognitive problems affect close to half of MS patients (Rao et al., 1991).
Imaging measures reﬂecting cortical gray matter MS pathology, such as
cortical thickness and assessment of cortical lesion numbers byDIR, cor-
relate with cognition in RRMS (Calabrese et al., 2009a; Morgen et al.,
2006), and SPMS (Benedict et al., 2006; Roosendaal S.D., 2009). In con-
trast, measures of white matter and deep graymatter pathology (lesion
volumes, black hole volumes, whitematter volumes) correlate less well
if at all with cognition (Roosendaal et al., 2011). Notably, cortical lesions
are conspicuously sparse in patients with “benign”MS (Calabrese et al.,
2009b).
Detection of cortical MS lesions using imaging in MS patients has
been challenging. DIR techniques can increase cortical lesion detection
(Calabrese et al., 2007b; Geurts et al., 2005b; Geurts et al., 2011), but
DIR is insensitive, missingmore than half of cortical MS lesions detected
by histopathology (Ceccarelli et al., 2012; Seewann et al., 2012). Ultra-
high ﬁeld MRI detects more cortical lesions, but it is not available in
most medical centers (Bluestein et al., 2012). Non-standard imaging
techniques have been applied to the detection of cortical MS lesions, in-
cluding magnetization transfer and diffusion tensor imaging. Cortical
abnormalities detected by magnetization transfer have been reported
(Chen et al., 2013; Derakhshan et al., 2014a, 2014b; Schmierer et al.,
2010; Seewann et al., 2011). The ﬁndings from these studies suggested
that high ﬁeld and high resolutionwere necessary for cortical lesion de-
tection using magnetization transfer ratio. Most of these studies were
done on post-mortem brains and validated in vivo results are needed
for applying this technique to clinical use. Diffusion tensor imaging is
Fig. 5. GEPCI-barcodes for all brain regions studied in all subjects. ΔR2* values were calculated for various regions (x-axis) of each HC and MS subject (y-axis). z-Score values were calcu-
latedusingmean value and standard deviation calculated fromage-dependentΔR2* values for eachROI in thewholeHC cohort.White squares represent z-score valueswithin the range−
1.96 to 1.96 of the HC subjects, considered normal. Red and blue colors represent low and highΔR2* values, respectively. Red empty squares represent z-score values less than−1.96 but
greater than−2.58. Red ﬁlled squares represent z-score values less than−2.58. Blue empty squares represent z-score values greater than 1.96 but less than 2.58. Blue ﬁlled squares rep-
resent z-score values greater than 2.58.
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duced fractional anisotropy). Diffusion measures have been reported
to correlate with disability, including cognitive dysfunction (Hulstet al., 2013; Vrenken et al., 2006). Application of diffusion measures in
cortical gray matter, and the associations with cognitive function are
still being elucidated (Llufriu et al., 2014).
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2000) is a relatively new technique, which provides high-resolution, co-
registered, multi-contrast images within a single scan that can be per-
formed in less than 7 min on standard MRI scanners (Luo et al., 2014).
In this study we explored two GEPCI images — T1w and R2* maps.
T1w images were used for image registration while R2* maps were
used to quantify tissue “health status”. BecauseGEPCI can provide quan-
titative R2* (and T2*)maps, it can be used to quantitatively detect subtle
tissue damage in different brain regions. Previously we used GEPCI to
quantitate tissue damage in white matter lesions (Sati et al., 2010). In
the present study, we report that the quantitative parameter R2* can
also evaluate tissue damage in cortical gray matter and in NAWM. Our
MS subject cohort showed overall substantially lower R2* values in
both cortical graymatter and NAWM (Fig. 2). GEPCI data appear to pro-
vide information that is complementary to the published atrophy data
(Benedict et al., 2006; Bermel et al., 2003; Calabrese et al., 2009a;
Morgen et al., 2006; Zivadinov et al., 2013). Indeed our results demon-
strated that not only volume but also health of the tissue as deﬁned by
R2* declined in brain regions that are also prone to suffer volume loss
in MS.
Based on quantitative R2* analysis, we introduced in this paper a
technique called “GEPCI-barcode” to illustrate regional GEPCI results,
with the idea that this method might be applied to individually label
each patient3s brain tissue “health status” and follow changes in the
patients3 brain tissue health longitudinally. Most MS subjects in our
studies had some cortical regions of R2* abnormality. Not unexpect-
edly, PPMS and SPMS subjects showed more widespread cortical ab-
normalities than RRMS subjects; this was readily apparent by
viewing data using GEPCI-barcode. Abnormalities of R2* were pre-
dominantly located in the frontal, temporal, central and cingulate
regions, including the caudal middle frontal, lateral orbitofrontal,
paracentral, postcentral, precentral, superior temporal and isthmus
of the cingulate gyrus cortical regions. Many previous studies also
found that it was mainly these same regions that showed cortical at-
rophy in MS patients (Narayana et al., 2012a; Ramasamy et al.,
2009b; van Munster et al., 2015).
Previous ex vivo studies have shown that bothwhitematter and cor-
ticalMS lesionshave shorter R2* (longer T2*) due tomyelin and iron loss
(Yao et al., 2012; Yao et al., 2014). In accord, ourMS cohort had substan-
tially lower R2* in cortical regions compared to the healthy cohort.
Moreover, GEPCI-barcode revealed more abnormal cortical regions in
the SPMS than PPMS cohort in our study. This result is consistent with
previous pathology studies that reported cortical demyelination in
SPMS subjects to bemorewidespread and severe than in PPMS subjects
(Howell et al., 2011; Magliozzi et al., 2007). The same study also sug-
gested that cortical damage was distributed throughout the forebrain,
especially in the deep sulci of the temporal, cingulate, insula and frontal
cortex. Our results are highly consistent with this. Recently, Mainero
et al. using high resolution T2* mapping obtained with high ﬁeld
(7 T) MRI revealed that cortical pathology has a depth dependence
(Mainero et al., 2015). Their results showed that in early MS, regions
with higher T2* (lower R2*) were mainly located in the outer layers in
the rostral anterior cingulate, parietal, precentral and postcentral re-
gions. As disease progressed, the regions with higher T2* spread to all
cortical depths and regions. Our averaged z-score map (Fig. 4) showed
a similar pattern with regard to affected regions. For RRMS, the regions
with lower z-scores are mainly located in the lateral occipital, parietal,
cuneus, pericalcarine, precuneus, precentral and postcentral regions.
For SPMS, almost all cortical regions showed low z-scores compared
to other groups.
From GEPCI-barcode, we also found that one RRMS, two PPMS and
four SPMS subjects showed reduced R2* in the hippocampus, a region
that is crucial for episodic memory. ΔR2* measurements in this region
correlated well with SDMT and PASAT scores (Fig. 3). In our study, 6
of 7 subjects with reduced R2* in the hippocampus on GEPCI-barcode
scored poorly on SDMT and PASAT testing. Again, our results areconsistent with studies in which hippocampal atrophy had been found
mainly in patients with severe cognitive impairment (Koenig et al.,
2014; Sicotte et al., 2008). These data strongly support our interpreta-
tion of reduced R2* to indicate hippocampal damage.
Quantitative R2* analysis of global cortical gray matter showed con-
vincing correlationswith clinical cognitive tests (SDMT and PASAT). Be-
cause both SDMT and PASAT assess cognitive function in which cortical
graymatter plays a critical role, this suggests that R2* can serve as a sen-
sitive biomarker to characterize tissue functional viability. Notably,ΔR2*
values in some speciﬁc cortical regions showed strong correlationswith
clinical cognitive tests. The correlation between the PASAT, ameasure of
auditory information processing speed, andΔR2* values of the superior-
temporal region, which is critical for auditory processing (r= 0.62, p=
0.01), supports the relevance of the GEPCI data.
We found no correlations between cortical ΔR2* values and EDSS,
25FTWand 9HPT. These results were initially surprising, given prior pa-
pers ﬁnding correlations between GM volumes and impairment mea-
sures such as EDSS and 25FTW. However, early studies with strong
correlations to EDSS often reported correlations for whole GM, includ-
ing subcortical GM structures (Fisher et al., 2008; Sanﬁlipo et al.,
2005). Others found only weak correlations between global or regional
cortical thickness and physical impairmentmeasures (Matsushita et al.,
2015; Narayana et al., 2012b) or none (Datta et al., 2015; Ramasamy
et al., 2009a). Many studies showing larger correlations have not
accounted for age (Calabrese et al., 2007a). Our results are in keeping
with the ﬁndings of Shiee et al., who found no correlation between cor-
tical volumes and EDSS, 25FTWand 9HPT inMS patients of varying sub-
types (Shiee et al., 2012). As the EDSS, 25FTW and 9HPT all measure
primarily motor function and coordination, where the cerebellum and
spinal cord play more important roles than the cerebral cortex, our re-
sults are not too surprising.
Importantly, our results show that regions of cortical atrophy not
only suffer tissue loss but also experience tissue structural changes. In-
deed, cortical damage detected by R2* measurements occurred mainly
in the same regions that showed cortical atrophy in previous reports
in MS patients (Narayana et al., 2012a; Ramasamy et al., 2009b). Our
data conﬁrmed volume loss in almost all of the same individual brain
regions. Volume loss has been reported to correlate with cognitive
impairment in RRMS (Calabrese et al., 2009a; Morgen et al., 2006). Lon-
gitudinal studies have also shown that volume loss correlates with dis-
ability (Popescu et al., 2013; Radue et al., 2015). In our cross-sectional
study, we found that regional cortical GM volumetric data showed sig-
niﬁcant differences between healthy and MS cohorts, but no signiﬁcant
correlations of regional volumes were found with cognitive tests
(Table A.2). In contrast, R2* data showed signiﬁcant correlations with
cognitive tests, suggesting that R2* can provide information on tissue
damage in the cortex that is different and complementary to volume
information.
In the deep nuclei area, especially in the globus pallidus, RRMS sub-
jects tended to have higher R2* values compared with age-matched HC
subjects (Table A.1). This is perhaps explained by excess iron accumula-
tion in these regions, but it was curious that our progressive SPMS and
PPMS cohorts demonstrated less alteration in R2* in the globus pallidus
than the RRMS cohort. The reason for this is unclear, but may relate to a
combination of both reduction of R2* due to tissue integrity loss and in-
crease in R2* due to iron which serve to off-set one another in the older
progressive patients to a larger degree than in the RRMS cohort.
Since cortical gray matter is relatively thin, it is important to apply
methods that would reduce the inﬂuence of partial volume effects, es-
pecially signal contamination by CSF. To address this issue in our studies
we used imaging with high in-plane resolution (1 mm × 1 mm). We
also applied a CSF mask to remove CSF signals that might contaminate
our results and we used statistical measurements instead of a voxel-
based analysis. For each region, which usually contains thousands of
voxels, we generated a single parameter—median value of R2* distribu-
tion because themedian value is less sensitive to outliers (that might be
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GM regions, we did multiple linear regression of R2* measurements
with both age and cortical thickness to account for age and atrophy
effects.5. Conclusion
Our ﬁndings showed that, overall, using tissue speciﬁc R2* measure-
ments we could detect and measure cortical abnormalities in MS pa-
tients using a standard MRI scanner, and with a very short clinically
acceptable scan time. The correlations between cognitive functioning
and speciﬁc graymatter R2* values provided evidence that R2* is intrin-
sically related to tissue-speciﬁc pathology, and R2* measurements can
be used to evaluate tissue integrity. These are critical ﬁndings, as the
ﬁeld has great need of a quantitative method to detect cortical damage
thatwill improve upon and complementmeasures of volume,which are
currently the most useful measure of cortical damage (Popescu et al.,
2013). Our results suggest that clinical trials, especially early phase trials
using imaging as a primary endpoint, might beneﬁt by including GEPCI
measures. In future studies, we will examine larger numbers of subjects
and employ methods to correct physiologically-induced artifacts (WenTable A.1
p-Values for group differences in 37 graymatter regions identiﬁed by FreeSurfer. Signiﬁcant p-v
was applied to all regions.
ROI ΔR2*
HC vs. RR HC vs. PP HC vs. SP RR vs. PP RR vs. SP
Caudal anterior cingulate 0.762 0.949 0.481 0.959 0.964
Caudal middle frontal 0.341 0.101 b0.001 0.819 0.039
Cuneus 0.041 0.577 b0.001 0.819 0.287
Fusiform 0.136 0.101 b0.001 0.986 0.100
Inferior parietal 0.278 0.071 b0.001 0.819 0.039
Inferior temporal 0.274 0.554 0.003 0.819 0.135
Isthmus of cingulate 0.436 0.357 0.004 0.986 0.300
Lateral
Occipital
0.041 0.071 b0.001 0.986 0.101
Lateral orbitofrontal 0.692 0.949 0.029 0.819 0.048
Lingual 0.077 0.306 b0.001 0.959 0.067
Medial orbitofrontal 0.432 0.889 0.609 0.819 0.284
Middle temporal 0.804 0.086 0.004 0.819 0.144
Parahippocampal 0.738 0.215 b0.001 0.819 0.039
Paracentral 0.302 0.128 b0.001 0.959 0.109
Pars opercularis 0.808 0.137 b0.001 0.819 0.018
Pars orbitalis 0.738 0.357 0.006 0.819 0.039
Pars triangularis 0.738 0.137 b0.001 0.819 0.004
Pericalcarine 0.260 0.889 0.001 0.819 0.145
Postcentral 0.432 0.159 b0.001 0.819 0.018
Posterior cingulate 0.723 0.531 0.352 0.985 0.860
Precentral 0.302 0.071 b0.001 0.819 0.039
Precuneus 0.077 0.071 b0.001 0.959 0.126
Rostral anterior cingulate 0.762 0.889 0.664 0.986 0.452
Rostral middle frontal 0.891 0.137 0.003 0.819 0.039
Superior frontal 0.738 0.137 0.001 0.819 0.039
Superior parietal 0.136 0.202 b0.001 0.986 0.101
Superior temporal 0.762 0.086 b0.001 0.819 0.027
Supramarginal 0.339 0.137 b0.001 0.819 0.039
Frontal pole 0.891 0.666 0.232 0.819 0.284
Transverse temporal 0.762 0.720 0.006 0.986 0.207
Insula 0.762 0.949 0.081 0.959 0.178
Thalamus 0.329 0.949 0.307 0.819 0.691
Caudate 0.762 0.282 0.380 0.828 0.325
Putamen 0.762 0.949 0.409 0.959 0.733
Globus pallidus 0.041 0.128 0.152 0.819 0.280
Hippocampus 0.762 0.889 0.008 0.986 0.065
Amygdala 0.136 0.625 0.473 0.819 0.372
Appendix Aet al., 2014). Our goal is to develop an easy and universally applicable
quantitative method to detect CNS damage to aid in patient manage-
ment and use in multi-center clinical trials.Funding
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Δ volume
PP vs. SP HC vs. RR HC vs. PP HC vs. SP RR vs. PP RR vs. SP PP vs. SP
0.598 0.741 0.385 0.083 0.807 0.302 0.804
0.263 0.195 0.154 0.184 0.999 0.916 0.960
0.255 0.049 0.021 0.003 0.999 0.458 0.804
0.244 0.009 0.001 b0.001 0.807 0.113 0.819
0.244 0.049 0.008 b0.001 0.807 0.120 0.804
0.244 0.084 0.050 0.328 0.999 0.684 0.819
0.411 0.643 0.530 0.528 0.807 0.896 0.804
0.244 0.058 0.007 b0.001 0.807 0.302 0.804
0.244 0.059 0.005 0.005 0.807 0.573 0.921
0.244 0.021 0.027 0.001 0.999 0.304 0.804
0.933 0.499 0.088 0.018 0.807 0.391 0.837
0.569 0.015 0.022 0.001 0.999 0.638 0.804
0.244 0.134 0.027 0.012 0.807 0.416 0.837
0.244 0.066 b0.001 0.001 0.012 0.302 0.804
0.244 0.049 0.002 0.009 0.807 0.702 0.837
0.299 0.088 0.005 0.017 0.807 0.638 0.804
0.244 0.011 0.005 b0.001 0.999 0.302 0.804
0.244 0.058 0.021 0.001 0.982 0.302 0.804
0.244 0.021 0.002 0.002 0.807 0.573 0.837
0.958 0.014 0.022 b0.001 0.999 0.197 0.804
0.314 0.039 0.001 0.003 0.800 0.521 0.819
0.275 0.039 0.006 0.007 0.807 0.521 0.960
0.598 0.313 0.343 0.009 0.999 0.348 0.804
0.299 0.058 0.040 0.014 0.999 0.638 0.861
0.244 0.160 0.003 0.009 0.800 0.442 0.804
0.244 0.016 0.001 0.001 0.800 0.302 0.960
0.275 0.006 0.003 b0.001 0.999 0.638 0.861
0.244 0.123 0.001 0.001 0.477 0.321 0.804
0.583 0.162 0.245 0.908 0.999 0.416 0.804
0.244 0.598 0.154 0.074 0.999 0.638 0.960
0.357 0.050 0.347 0.030 0.807 0.971 0.804
0.583 0.039 0.006 0.003 0.999 0.855 0.960
0.244 0.006 b0.001 0.001 0.863 0.865 0.804
0.569 b0.001 0.001 b0.001 0.999 0.573 0.819
0.871 0.008 0.006 b0.001 0.999 0.397 0.804
0.244 0.149 0.166 0.020 0.999 0.521 0.804
0.988 0.110 0.088 0.002 0.999 0.370 0.804
Table A.2
Correlations between cognitive test scores andΔR2* in 37 graymatter brain regions. Signiﬁcant correlations (r N 0.4, p b 0.05) are in bold. False discovery rate [FDR] correction formultiple
comparisons was applied to all regions.
ROI ΔR2* Δ volume
SDMT PASAT (3 s) SDMT PASAT (3 s)
r p r p r p r p
Caudal anterior cingulate 0.233 0.275 0.352 0.084 0.317 0.300 0.278 0.497
Caudal middle frontal 0.557 0.014 0.480 0.034 0.259 0.370 0.176 0.800
Cuneus 0.460 0.028 0.408 0.054 0.270 0.370 0.041 0.878
Fusiform 0.551 0.014 0.501 0.026 0.393 0.220 0.360 0.347
Inferior parietal 0.514 0.018 0.517 0.023 0.424 0.207 0.473 0.307
Inferior temporal 0.350 0.100 0.192 0.356 0.246 0.370 0.198 0.768
Isthmus of cingulate 0.236 0.275 0.364 0.074 0.378 0.233 0.296 0.452
Lateral occipital 0.318 0.133 0.340 0.094 0.548 0.080 0.415 0.307
Lateral orbitofrontal 0.417 0.045 0.383 0.062 0.023 0.931 0.060 0.878
Lingual 0.533 0.016 0.412 0.054 0.188 0.432 −0.041 0.878
Medial orbitofrontal 0.343 0.106 0.263 0.200 0.110 0.658 0.062 0.878
Middle temporal 0.299 0.158 0.388 0.061 0.198 0.427 0.331 0.430
Parahippocampal 0.484 0.025 0.410 0.054 0.350 0.266 0.065 0.878
Paracentral 0.200 0.356 0.264 0.200 0.332 0.299 0.147 0.808
Pars opercularis 0.474 0.025 0.405 0.054 0.203 0.424 0.158 0.808
Pars orbitalis 0.424 0.043 0.395 0.057 −0.309 0.300 −0.236 0.634
Pars triangularis 0.474 0.025 0.525 0.023 0.310 0.300 0.170 0.800
Pericalcarine 0.473 0.025 0.421 0.054 0.181 0.440 −0.044 0.878
Postcentral 0.453 0.029 0.442 0.047 0.228 0.387 0.086 0.878
Posterior cingulate 0.047 0.854 0.148 0.468 0.193 0.428 0.078 0.878
Precentral 0.557 0.014 0.396 0.057 0.292 0.338 0.203 0.768
Precuneus 0.468 0.026 0.457 0.040 0.115 0.657 0.007 0.970
Rostral anterior cingulate 0.166 0.452 0.193 0.356 0.259 0.370 0.099 0.878
Rostral middle frontal 0.525 0.016 0.458 0.040 0.069 0.783 −0.046 0.878
Superior frontal 0.423 0.043 0.406 0.054 0.155 0.518 0.029 0.907
Superior parietal 0.403 0.053 0.295 0.153 0.222 0.390 0.135 0.821
Superior temporal 0.570 0.014 0.615 0.014 0.238 0.370 0.170 0.800
Supramarginal 0.596 0.014 0.539 0.023 0.238 0.370 0.241 0.634
Frontal pole 0.376 0.075 0.532 0.023 0.050 0.843 −0.081 0.878
Transverse temporal 0.487 0.025 0.515 0.023 0.211 0.414 0.153 0.808
Insula 0.322 0.131 0.456 0.040 0.087 0.730 0.089 0.878
Thalamus 0.014 0.943 0.054 0.782 0.444 0.201 0.302 0.452
Caudate 0.148 0.496 0.092 0.651 0.010 0.960 −0.091 0.878
Putamen −0.064 0.805 −0.170 0.412 0.405 0.220 0.300 0.452
Globus pallidus −0.032 0.892 −0.379 0.063 0.368 0.236 0.382 0.312
Hippocampus 0.532 0.016 0.584 0.016 0.449 0.201 0.423 0.307
Amygdala 0.238 0.275 0.405 0.054 0.279 0.361 0.131 0.821
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